Atlas Trials

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Clinical trial NCT04262804 · UNKNOWN

Trial details

NCT number
NCT04262804
Sponsor
Zai Lab (Shanghai) Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer Metastatic
Start date
2020-01-13
Primary completion
2021-09-03
Enrollment
123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.